source
- FDA rejects Capricor’s Duchenne cell therapy after trials show no benefitThe Food and Drug Administration announced that it is rejecting deramiocel, a cell therapy for Duchenne muscular dystrophy developed by Capricor Therapeutics. The treatment was aimed at teenage an…
- Heraeus Medevio issues recall of vascular guidewires over coating safety riskThe FDA's Center for Devices and Radiological Health has posted an Early Alert warning about a potentially high‑risk issue with certain vascular guidewires. The alert notes that the coating on the…